ZLB Behring is a global leader in the manufacture of plasma therapeutics with the broadest range of quality products in our industry and substantial markets in the USA, Europe and Japan.

Based at King of Prussia in Pennsylvania (USA), ZLB Behring has manufacturing plants in Kankakee, Illinois (USA), Bern (Switzerland) and Marburg (Germany), and sales and distribution centres throughout the world.

Our plasma therapeutics include:

• Coagulation therapies to treat bleeding disorders such as haemophilia;
• Critical care products for treatment of shock in trauma, sepsis, severe burns and cardiac surgery;
• Immunoglobulins to treat infections and autoimmune diseases, and to prevent haemolytic disease in the newborn;
• Wound treatment therapies used to minimise blood loss.
• Alpha-1-Proteinase Inhibitor, a prophylactic treatment for people at risk from life-shortening, inherited emphysema.

We understand the needs of people who rely on our products. Those with haemophilia (a bleeding disorder resulting in poor blood clotting and continuous bleeding) have to learn to live with this life-threatening condition. People can suffer severe blood plasma losses in emergency trauma situations and with serious burns. Some patients have wounds that continue bleeding, or immune systems too weak to fight infection.

ZLB Behring provides a wide variety of programs and services to improve patient access to care and quality of life.

ZLB Behring is well positioned to develop its global business in plasma therapeutics through our broad portfolio of high quality products, global marketing that meets customer needs, a pipeline of new and improved plasma products, lower cost and higher yield manufacturing processes, and effective balancing of supply and demand.

Manufacturing is focused on core product strengths at each location and cost effective operations that create more return for each litre of plasma processed.

Since creating manufacturing centres of excellence, we have brought a sharper focus on life cycle management, the product pipeline, process development and product safety.

• Marburg develops coagulation therapies, along with critical care and specialty products;
• Bern focuses on immunoglobulins, production methods and safety standards;
• Kankakee is responsible for the continuous improvement of Alpha-1-Proteinase Inhibitor.

Back | Next